Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
暂无分享,去创建一个
E. Kimby | E. Montserrat | W. Wiktor-Jedrzejczak | M. Hallek | D. Niederwieser | P. Dreger | P. Corradini | D. Milligan | M. Michallet | J. Schetelig | M. Michallet
[1] S. Deaglio,et al. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. , 2006, Blood.
[2] K. Do,et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Axel Benner,et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Giné,et al. How I treat refractory CLL. , 2006, Blood.
[5] M. Caligiuri,et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] E. Giné,et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. , 2005, Blood.
[7] E. Montserrat,et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. , 2005, Blood.
[8] Marcos González,et al. Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q− and 17p−) , 2005, Clinical Cancer Research.
[9] P. Bierman,et al. Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] N. Schmitz,et al. The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile? , 2005, Leukemia.
[11] K. Do,et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Andreeff,et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Radich,et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Brand,et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis , 2005, Leukemia.
[15] A. López-Guillermo,et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Gribben. Salvage therapy for CLL and the role of stem cell transplantation. , 2005, Hematology. American Society of Hematology. Education Program.
[17] N. Schmitz,et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. , 2004, Blood.
[18] Lisa L. Smith,et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. , 2004, Blood.
[19] J. Byrd,et al. Chronic lymphocytic leukemia. , 2004, Hematology. American Society of Hematology. Education Program.
[20] W. Siegert,et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Adrian Wiestner,et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. , 2003, Blood.
[22] Emili Montserrat,et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.
[23] N. Chiorazzi,et al. B Cell Chronic Lymphocytic Leukemia , 2003 .
[24] T. Möröy,et al. Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. , 2003, Blood.
[25] J. Byrd,et al. Chronic lymphocytic leukemia. , 2010, Hematology. American Society of Hematology. Education Program.
[26] E. Giné,et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia , 2002, British journal of haematology.
[27] E. Montserrat,et al. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia , 2002, Leukemia.
[28] J. Byrd,et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.
[29] M. Keating,et al. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. , 2002, Cytotherapy.
[30] J. Byrd,et al. Frequency and type of serious infections in fludarabine‐refractory B‐cell chronic lymphocytic leukemia and small lymphocytic lymphoma , 2002, Cancer.
[31] J. Esteve,et al. Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia. , 2002, Blood.
[32] H. Kantarjian,et al. Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia , 2002, Leukemia & lymphoma.
[33] D. Catovsky,et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. , 2001, Blood.
[34] H. Kantarjian,et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[36] T J Hamblin,et al. Immunoglobulin V genes and CD38 expression in CLL. , 2000, Blood.
[37] E. Kimby,et al. Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease , 2000, Leukemia.
[38] M. Bishop,et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia , 2000, Bone Marrow Transplantation.
[39] T J Hamblin,et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.
[40] N. Chiorazzi,et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.
[41] R. Foà,et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. , 1999, Blood.
[42] Terry J. Hamblin,et al. Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia , 1999 .
[43] E J Freireich,et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. , 1998, Blood.
[44] M. Andreeff,et al. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. , 1996, Bone marrow transplantation.
[45] E. Montserrat,et al. HLA-Identical Sibling Bone Marrow Transplantation in Younger Patients with Chronic Lymphocytic Leukemia , 1996, Annals of Internal Medicine.
[46] A Benner,et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.